Mesoblast (MESO) EBITDA (2014 - 2023)

Mesoblast has reported EBITDA for 10 years, with the latest figure at -$17.5 million in Q2 2023.

• Quarterly EBITDA fell 17964.29% year-over-year to -$17.5 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was -$46.7 million (up 19.78% YoY) and the FY2025 annual result came in at -$62.0 million, down 5.53% from the prior year.
• EBITDA fell to -$17.5 million in Q2 2023 per MESO's latest filing, from -$3.0 million in the prior quarter.
• Over five years, EBITDA peaked at $98000.0 in Q2 2022 and troughed at -$31.4 million in Q4 2021.
• A 5-year average of -$16.5 million and a median of -$17.8 million in 2021 frame the typical range for EBITDA.
• The sharpest annual moves came in 2022 and 2023: EBITDA jumped 100.54% in 2022, then plunged 17964.29% in 2023.
• Over 5 years, EBITDA stood at -$23.3 million in 2019, then rose by 7.0% to -$21.6 million in 2020, then plunged by 45.23% to -$31.4 million in 2021, then soared by 55.83% to -$13.9 million in 2022, then retreated by 26.2% to -$17.5 million in 2023.
• According to Business Quant data, EBITDA over the past three periods registered -$17.5 million, -$3.0 million, and -$13.9 million for Q2 2023, Q1 2023, and Q4 2022 respectively.